Oncosil Medical Share Purchase Plan
Filed with ASX · · 26 pages · English
Sydney, Australia, 28 March 2018: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to offer eligible Oncosil Medical shareholders the opportunity to participate in the Oncosil Medical Share Purchase Plan (SPP), as announced on 21 March 2018. A booklet containing det
Earlier from OncoSil Medical
- Successful Completion of Capital Raising
- Presentation-Surgical Resection Outcomes and Capital Raising
- Positive Early Study Results Continue
- Appendix 4D & Half Yearly Report and Accounts
- First Subject Recruited in the United States
Later from OncoSil Medical
- Clinical Programme Update
- Oncosil submits Clinical Study Report to Notified Body
- Response to Price Query
- Appendix 4C & Quarterly Update
- Preliminary Final Report
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical